vs
Side-by-side financial comparison of Regencell Bioscience Holdings Ltd (RGC) and USANA HEALTH SCIENCES INC (USNA). Click either name above to swap in a different company.
Regencell Bioscience Holdings Ltd is a specialized bioscience enterprise focused on the research, development and commercialization of therapeutic products derived from traditional Chinese medicine. Its core pipeline targets neurodegenerative, immunological and infectious disease treatments, with primary operating markets across Greater China and other Asian regions.
Usana Health Sciences, Inc., or USANA, is an American multi-level marketing company based in Salt Lake City, Utah. As of 2021, Usana was the 14th largest direct-selling company in the world by revenue. The company manufactures most of its nutritional products, dietary supplements, and skincare products at a Salt Lake City facility. Its products are sold in 24 countries via a network of independent distributors.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $213.7M | ||
| Q2 25 | — | $235.8M | ||
| Q1 25 | — | $249.5M | ||
| Q4 24 | — | $213.6M | ||
| Q3 24 | — | $200.2M | ||
| Q2 24 | — | $212.9M | ||
| Q1 24 | — | $227.8M | ||
| Q4 23 | — | $221.1M |
| Q3 25 | — | $-6.5M | ||
| Q2 25 | — | $9.7M | ||
| Q1 25 | — | $9.4M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | — | $10.6M | ||
| Q2 24 | — | $10.4M | ||
| Q1 24 | — | $16.5M | ||
| Q4 23 | — | — |
| Q3 25 | — | 77.2% | ||
| Q2 25 | — | 78.7% | ||
| Q1 25 | — | 79.0% | ||
| Q4 24 | — | 82.0% | ||
| Q3 24 | — | 80.4% | ||
| Q2 24 | — | 81.1% | ||
| Q1 24 | — | 81.1% | ||
| Q4 23 | — | 80.9% |
| Q3 25 | — | 0.6% | ||
| Q2 25 | — | 7.1% | ||
| Q1 25 | — | 6.3% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | 7.8% | ||
| Q2 24 | — | 8.4% | ||
| Q1 24 | — | 10.8% | ||
| Q4 23 | — | 11.0% |
| Q3 25 | — | -3.1% | ||
| Q2 25 | — | 4.1% | ||
| Q1 25 | — | 3.8% | ||
| Q4 24 | — | 2.1% | ||
| Q3 24 | — | 5.3% | ||
| Q2 24 | — | 4.9% | ||
| Q1 24 | — | 7.3% | ||
| Q4 23 | — | — |
| Q3 25 | — | $-0.36 | ||
| Q2 25 | — | $0.52 | ||
| Q1 25 | — | $0.49 | ||
| Q4 24 | — | $0.23 | ||
| Q3 24 | — | $0.56 | ||
| Q2 24 | — | $0.54 | ||
| Q1 24 | — | $0.86 | ||
| Q4 23 | — | $0.87 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
